España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
PsyBio Therapeutics
PSYBF
OTCEM
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
Get Report
Comment
PsyBio Therapeutics (PSYBF) Forecast
News
Earnings
PsyBio Therapeutics (PSYBF) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for PsyBio Therapeutics (OTC:PSYBF) Stock
PsyBio Therapeutics Stock (OTC: PSYBF)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, June 08, 2023
MA, FL And OH Psychedelics Scientists And Educators' Latest Research And Views
Lara Goldstein
Friday, April 14, 2023
EXCLUSIVE: In Reinventing Mental Health & Next-Gen Psychedelics, 'Access And Clinical Data Are Key'
Joana Scopel
Tuesday, December 13, 2022
Psyched: Psychedelic Therapy In The Workplace, UCL's Brain Imaging Study, COMPASS Trials And More
Lara Goldstein
Monday, December 12, 2022
Psychedelics & Environmental Protection: Company Seeks Patents To Synthetically Produce Toad Venom
Lara Goldstein
Wednesday, December 07, 2022
Psychedelics Production Methods Expect Further IP Protection With 4 New Patents
Lara Goldstein
Tuesday, December 06, 2022
Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project
Lara Goldstein
Friday, December 02, 2022
PsyBio Therapeutics Reports Interim Third Quarter 2022 Financial Results
Joana Scopel
Tuesday, October 11, 2022
Yeast Produces Bread And Psilocybin, This Company Is Moving Into Clinical Trial Phase
Lara Goldstein
Tuesday, September 06, 2022
Most, But Not All, Psychedelics Companies Have Sufficient Liquidity
Viridian Capital Advisors
Monday, August 29, 2022
DMT Producer PsyBio And Shrooms Grower Red Light Holland Share Their Most Recent Financial Results
Lara Goldstein
Friday, April 29, 2022
PsyBio Therapeutics Presents "How Genetically Modified Bacteria Can Yield Best-In-Class Psychedelics" At The Psychedelic Capital Conference
Jad Malaeb
-
Sponsored
Monday, January 24, 2022
Cannabis Movers & Shakers: Burns & Levinson, Water Ways, Chill Brands, Rubicon Organics
Jelena Martinovic
Monday, October 18, 2021
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
Natan Ponieman
Wednesday, October 13, 2021
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Natan Ponieman
Monday, September 27, 2021
Psyched: Delic Buys 10 Ketamine Clinics For $10M, Atai Launches Ibogaine Human Trials, Small Pharma Concludes Phase 1 DMT Study
Natan Ponieman
Friday, July 02, 2021
Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies
Natan Ponieman
Wednesday, June 30, 2021
Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More
Natan Ponieman
